Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Long-Term Deferred Tax: 2021-2023

Historic Long-Term Deferred Tax for ADC Therapeutics (ADCT) over the last 2 years, with Sep 2023 value amounting to $35.4 million.

  • ADC Therapeutics' Long-Term Deferred Tax rose 5.36% to $35.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $35.4 million, marking a year-over-year increase of 5.36%. This contributed to the annual value of $37.1 million for FY2022, which is 42.44% up from last year.
  • Latest data reveals that ADC Therapeutics reported Long-Term Deferred Tax of $35.4 million as of Q3 2023, which was up 1.66% from $34.8 million recorded in Q2 2023.
  • ADC Therapeutics' Long-Term Deferred Tax's 5-year high stood at $37.1 million during Q4 2022, with a 5-year trough of $26.0 million in Q4 2021.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $33.8 million (2022), whereas its average is $32.3 million.
  • As far as peak fluctuations go, ADC Therapeutics' Long-Term Deferred Tax spiked by 42.44% in 2022, and later declined by 7.69% in 2023.
  • ADC Therapeutics' Long-Term Deferred Tax (Quarterly) stood at $26.0 million in 2021, then spiked by 42.44% to $37.1 million in 2022, then increased by 5.36% to $35.4 million in 2023.
  • Its Long-Term Deferred Tax stands at $35.4 million for Q3 2023, versus $34.8 million for Q2 2023 and $27.6 million for Q1 2023.